
Score
43
Technically Neutral
Advice
Dr. Reddy's Laboratories Share Price - 1 Year Trend
Dr. Reddy's Laboratories Price Change Analysis
-
P/E Ratio
44.2
-
PEG Ratio
2.8
-
Market Cap Cr
71730.2
-
Price to Book Ratio
1101.7
-
EPS
97.5
-
Dividend
600 ()
-
Relative Strength Index
54.91
-
Money Flow Index
52.68
-
MACD Signal
27.32
-
Average True Range
109.27
Investment Ratings
-
Master Rating:
-
EPS Strength
Price Strength
Buyer Demand
Group Rank
Result Highlights
Dr. Reddy's Laboratories Synopsis
NSE-Medical-Diversified
Dr. Reddy's Labs is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 13349.10 Cr. and Equity Capital is Rs. 83.20 Cr. for the Year ended 31/03/2021. Dr. Reddy's Laboratories Ltd. is a Public Limited Listed company incorporated on 24/02/1984 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L85195TG1984PLC004507 and registration number is 004507.-
Market Cap
71,730.24
-
Sales
14,405.20
-
Shares in Float
-
No of Funds
696
-
Yield
0.7
-
Book Value
3.91
-
U/D Vol Ratio
1.5
-
LTDebt/Equity
0
-
Alpha
-0.07
-
Beta
0.65
Owner Name | Jun-21 |
---|---|
Promoters | 26.73% |
Mutual Funds | 12.42% |
Insurance Companies | 2.6% |
Foreign Portfolio Investors | 29.04% |
Financial Institutions/ Banks | 0.06% |
Individual Investors | 7.76% |
Others | 21.39% |
Name | Designation |
---|---|
Mr. K Satish Reddy | Chairman |
Mr. G V Prasad | Co-Chairman & Manag. Director |
Mr. Leo Puri | Independent Director |
Mr. Prasad R Menon | Independent Director |
Ms. Shikha Sharma | Independent Director |
Mr. Allan Oberman | Independent Director |
Dr. Bruce L A Carter | Independent Director |
Ms. Kalpana Morparia | Independent Director |
Mr. Sridar Iyengar | Independent Director |
Dr. Reddy's Laboratories Forecast
Price Estimates
Eps And Sales Estimates
Dr. Reddy's Laboratories Financials
- Quarterly P&L
- Annual P&L
- Cash Flow
- Balance Sheet
- Ratios
Dr. Reddy's Laboratories Technicals
EMA & SMA
CURRENT PRICE
EMA
Dr. Reddy's Laboratories Resistance and Support
Dr. Reddy's Laboratories Delivery and Volume
Dr. Reddy's Laboratories Price Change Analysis
Corporate Action
Similar Stocks
Company Name | 52 Week () |
Market Price () | Volume |
---|
Videos
About Company
News
FAQs
Dr Reddys Laboratories stock price CAGR for 10 Years stands at 12%, 5 Years at 8%, 3 Years at 20%, and 1 Year at -2%.
The ROE of Dr Reddys Laboratories is 11%.
Dr Reddy's Laboratories has an operating revenue of Rs. 20,442.10 Cr. on a trailing 12-month basis. Annual revenue growth of 7% is good, Pre-tax margin of 15% is great. As per analysts rating in the last 6 months, the recommendation is to HOLD Dr Reddys Laboratories.
Erez Israeli is the Chief Executive Officer (CEO) at Dr Reddy's Laboratories since 1 Aug 2019.